Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04837664
Other study ID # KingSaudUni
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date July 3, 2018
Est. completion date May 1, 2021

Study information

Verified date April 2021
Source King Saud University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cigarette smoking in conjugation with bad oral hygiene is considered a typical predisposing factor for many oral diseases including denture stomatitis. This study investigated the effect of Rose Bengal (RB)-and Curcumin (CUR)-mediated photodynamic therapy (PDT) in comparison with nystatin therapy in the intervention of denture stomatitis in cigarette smokers. Overall, 45 habitual cigarette smokers aged ~58 years having denture stomatitis were categorized into three groups: Group-I - RB-mediated PDT, Group-II - CUR-mediated PDT, and Group-III - Nystatin therapy. The primary outcome of the interest was: counts of Candida colony from denture surface and palatal mucosa, calculated as CFU/mL, whereas the prevalence of Candida species determined in 3 research groups comprised the secondary outcome. Oral swab specimens were gathered from the denture surfaces and palatal mucosa. All clinical assessments were performed at baseline, 6 weeks, and 12 weeks. C. albicans was the most prevalent yeast identified on both denture surfaces and palatal mucosa, followed by C. tropicalis and C. glabrata. A considerable decrease in the CFU/mL scores were observed in Group-I and Group-II at the end of the interventions and on the 12-week follow-up (p<0.05). Group-I, II, and III demonstrated clinical efficacy rates of 53%, 51%, and 49%, respectively. CUR-and RB-mediated PDT was found to be as effective as topical Nystatin therapy for the intervention of denture stomatitis among cigarette smokers.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 45
Est. completion date May 1, 2021
Est. primary completion date December 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria: The inclusion criteria consisted of the following: (1) completely edentulous participants; (2) removable complete denture wearers diagnosed with denture stomatitis (loss of filiform papillae, erythema, and feeling of mucosal burning); and (3) habitual cigarette smokers (individuals smoking at least 1 cigarette per day since =3 years). Exclusion Criteria: The exclusion criteria consisted of the following: (1) individuals who received steroids, antifungals, or antibiotics over the past 90 days before the initiation of the study; (2) lactating or pregnant women; (3) individuals who had been using the same denture over the past ten years; individuals who underwent cancer treatment (chemotherapy or radiotherapy); (5) patients who are immunocompromised, anemics, or diabetics; (6) habitual alcohol drinkers; and (7) participants who refused to sign the informed consent document.

Study Design


Intervention

Drug:
Curcumin
Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
Rose Bengal
Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
Nystatin
Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds

Locations

Country Name City State
Saudi Arabia King Saud University Riyadh

Sponsors (1)

Lead Sponsor Collaborator
King Saud University

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Candida albican Counts of Candida colony calculated as colony forming unit (CFU)/mL 12 weeks
Secondary Candida species Prevalence of other Candida species 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Active, not recruiting NCT02643914 - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A
Active, not recruiting NCT02629679 - Sports, Education and Consumption of Substances in Adolescents N/A
Completed NCT02218281 - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation N/A
Completed NCT02385227 - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes N/A
Completed NCT01199380 - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms Phase 2
Completed NCT00756704 - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department N/A
Completed NCT01692353 - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers N/A
Completed NCT00802919 - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Phase 4
Completed NCT01081119 - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth Phase 2
Completed NCT00682474 - School Nurse-Delivered Smoking Cessation Intervention Phase 2/Phase 3
Active, not recruiting NCT05520775 - Semaglutide for Alcohol Use Disorder Phase 2
Terminated NCT03840694 - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior N/A
Not yet recruiting NCT06032793 - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness. N/A
Terminated NCT03326128 - High Dose Bupropion for Smoking Cessation - Pilot Study Phase 2
Recruiting NCT03218670 - Your Health in On Click N/A
Completed NCT02538042 - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue) N/A
Completed NCT02792426 - Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users Phase 1